North America Bleeding Disorders Treatment Market Research Report - Segmented By Drug Class, Type & Country(U.S, Canada & Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2024 to 2029)

Updated On: January, 2024
ID: 3230
Pages: 141

North America Bleeding Disorders Treatment Market Size & Growth (2023 to 2028):

As per the research report, the size of the North America Bleeding Disorders Treatment Market is valued at USD 4.19 billion in 2023 and is estimated to grow at a CAGR of 7.80%, to reach USD 6.10 billion by 2028 during the forecast period 2023 to 2028.

Bleeding disorder treatment market growth has been driven mainly by Yo-y growth in patient numbers and the development of new therapies. As the number of people with bleeding disorders increases, the market for bleeding disorder therapies is expected to grow. There are approximately 1,125,000 males worldwide with a hereditary bleeding problem, with 418,000 having a mild form of the illness that often goes undetected. 

According to the CDC, about 1% of the general population is affected by Von Willebrand disease. By contrast, women are more likely to contract Von Willebrand disease because of their menstrual cycle. As a result, more patients have been treated with some approach, resulting in a market boom for bleeding problem therapy.

Businesses and governments are also driving innovation in bleeding disorder treatments. As a result, many corporations and scientific institutes have developed new drugs and improved existing ones to boost patient awareness of therapy and increase adoption rates. As a result, St. Jude's specialists and physicians have treated and improved bleeding problems for more than 50 years. 

Children's treatment services around the country work with a federally designated Hemophilia Rehab Centre. Additionally, researchers at Children's Hospital of Philadelphia have developed a gene therapy vector that could be more effective and safer for treating bleeding disorders, particularly sickle cell disease. 

Many alternative drugs are available with more straightforward administration methods, low immunogenicity, greater potency, and longer half-lives. In addition, during the past five years, bioengineering advances have assisted in treating bleeding disorders. As a result, the market for the treatment of bleeding disorders has grown significantly. 

Various factors such as high treatment costs will likely limit the growth of bleeding disorder treatments in North America.

High treatment costs represent an essential barrier to bleeding disorder treatment. Most middle-income countries cannot afford the high costs of outpatient appointments, hospitalizations, and laboratory tests. This means that it cannot treat bleeding disorders in these regions. 

A shortage of clinicians hinders the bleeding disorder treatment market in emerging and underdeveloped countries and unfavorable reimbursement policies. It is challenging for this market because of the lack of skilled practitioners to treat these conditions.

This research report on the North America Bleeding Disorders Treatment Market has been segmented and sub-segmented into the following categories:

By Drug Class: 

  • Fibrin Sealant
  • Desmopressin
  • Antibrinolytics
  • Recombinant Coagulation Factor Concentrates
  • Plasma Derived Coagulation Factor Concentrates

By Type:

  • vWD
  • Hemophilia A
  • Hemophilia B

By Country:

  • U.S
  • Canada
  • Rest of North America

Geographically, the North American region holds a significant share globally during the forecast period due to the rapid development of pharmaceutical companies operating in this region.

The U.S Bleeding Disorders Treatment Market is predicted to reach a decent CAGR. It will dominate the North American market because of the early adoption of developed medical technologies. More than 20,000 Americans have Hemophilia, and approximately 1% are living with Von Willebrand Disease (VWD), according to the Hemophilia Federation of America. 

The Canada Bleeding Disorders Treatment Market has the most significant share globally to reach growth significantly during the forecast period, and this market is expected to be healthy in this region due to its highly developed healthcare infrastructure, along with increasing investment in research and development, is also playing a pivotal role in enhancing market growth in the area. 

According to the World Federation of Hemophilia, approximately 18 thousand people have hemophilia, and over 11 thousand people have von Willebrand disease in the United States. In addition to around four hundred babies diagnosed with hemophilia A every year, approximately one in 5,000 male babies is affected.


Companies leading a dominant role in the North America Bleeding Disorders Treatment Market profiled in this report are Janssen North America Services, LLC and Grifos SA, Novo Nordisk, Bayer AG, Biogen Inc., Shire Plc., Medline Plus, Pfizer Inc, CSL Behring.,

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample